Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Spironolactone

FDA-approved product (tablet, oral), marketed as Aldactone, Carospir, Spironolactone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Spironolactone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ascites
  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Essential hypertension
  • Heart failure
  • Hepatic fibrosis
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia
  • Primary hyperaldosteronism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Aldosterone Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Spironolactone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Spironolactone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RELieving Increasing oEdema Due to Heart Failure

    NCT04142788 · start 2020-08-26

    Registered record
    Registry ID
    NCT04142788
    Conditions
    Heart Failure，Congestive
    Interventions
    Patiromer
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-08-26
    Completion
    2022-12-20
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure，Congestive
    InterventionPatiromer
    PhasePhase 4
    Registry statusTerminated

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?

    NCT04075149 · start 2019-12-18

    Registered record
    Registry ID
    NCT04075149
    Conditions
    Polycystic Ovary Syndrome; Puberty Disorders; Ovulation Disorder
    Interventions
    Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2019-12-18
    Completion
    2024-09-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Puberty Disorders; Ovulation Disorder
    InterventionSpironolactone
    PhaseEarly phase 1
    Registry statusUnknown

  • Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients

    NCT03953950 · start 2019-10

    Registered record
    Registry ID
    NCT03953950
    Conditions
    End Stage Renal Disease; Peritoneal Dialysis
    Interventions
    Spironolactone; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-10
    Completion
    2020-12
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Peritoneal Dialysis
    InterventionSpironolactone; Losartan
    PhasePhase 4
    Registry statusUnknown

  • Spironolactone Therapy In Young Women With NASH

    NCT03576755 · start 2019-01-09

    Registered record
    Registry ID
    NCT03576755
    Conditions
    NASH - Nonalcoholic Steatohepatitis
    Interventions
    Spironolactone 100mg; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-01-09
    Completion
    2023-07-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNASH - Nonalcoholic Steatohepatitis
    InterventionSpironolactone 100mg; Placebo oral capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

    NCT03502031 · start 2018-10-01

    Registered record
    Registry ID
    NCT03502031
    Conditions
    Renal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    Interventions
    Renin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-10-01
    Completion
    2024-10-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic; Diabetic Nephropathy Type 2
    InterventionRenin-Angiotensin (RAAS) alone; Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

    NCT03652623 · start 2018-07-23

    Registered record
    Registry ID
    NCT03652623
    Conditions
    HIV/AIDS; Gender; Behavior and Behavior Mechanisms
    Interventions
    TDF/FTC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-07-23
    Completion
    2023-11-30
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Gender; Behavior and Behavior Mechanisms
    InterventionTDF/FTC
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Role of Active Deresuscitation After Resuscitation-2

    NCT03512392 · start 2018-04-10

    Registered record
    Registry ID
    NCT03512392
    Conditions
    Critical Illness; Sepsis; Trauma
    Interventions
    Conservative fluid and deresuscitation strategy; Usual care strategy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-04-10
    Completion
    2021-07-17
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Sepsis; Trauma
    InterventionConservative fluid and deresuscitation strategy; Usual care strategy
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.

    NCT03334682 · start 2018-01-31

    Registered record
    Registry ID
    NCT03334682
    Conditions
    Acne Vulgaris
    Interventions
    spironolactone; Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-31
    Completion
    2023-07-04
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventionspironolactone; Doxycycline
    PhasePhase 3
    Registry statusCompleted

  • Tissue K+ in Primary Hyperaldosteronism

    NCT04251780 · start 2018-01-01

    Registered record
    Registry ID
    NCT04251780
    Conditions
    Primary Hyperaldosteronism; Electrolyte Disturbance
    Interventions
    Surgical Treatment of Primary Aldosteronism; Drug treatment of Primary Aldosteronism
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2024-04-24
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hyperaldosteronism; Electrolyte Disturbance
    InterventionSurgical Treatment of Primary Aldosteronism; Drug treatment of Primary Aldosteronism
    PhaseNot recorded
    Registry statusCompleted

  • The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

    NCT03329443 · start 2017-09-01

    Registered record
    Registry ID
    NCT03329443
    Conditions
    Acute Kidney Injury; IHD; Contrast-induced Nephropathy
    Interventions
    Spironolactone; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2018-09-04
    Enrolment
    490

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury; IHD; Contrast-induced Nephropathy
    InterventionSpironolactone; Placebo Oral Tablet
    PhasePhase 2
    Registry statusCompleted

  • The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

    NCT02483195 · start 2016-08

    Registered record
    Registry ID
    NCT02483195
    Conditions
    Female Androgenetic Alopecia
    Interventions
    5% Minoxidil; 200mg Spironolactone; 5mg Finasteride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-08
    Completion
    2018-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Androgenetic Alopecia
    Intervention5% Minoxidil; 200mg Spironolactone; 5mg Finasteride; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents

    NCT03981861 · start 2016-07-02

    Registered record
    Registry ID
    NCT03981861
    Conditions
    PCOS
    Interventions
    Metformin and Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-07-02
    Completion
    2019-06-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS
    InterventionMetformin and Spironolactone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

    NCT02501213 · start 2016-05-30

    Registered record
    Registry ID
    NCT02501213
    Conditions
    Cancer
    Interventions
    Spironolactone (+/- Furosemide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-05-30
    Completion
    2018-12-24
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionSpironolactone (+/- Furosemide)
    PhasePhase 2
    Registry statusTerminated

  • Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial

    NCT02169089 · start 2016-01

    Registered record
    Registry ID
    NCT02169089
    Conditions
    Atherosclerosis
    Interventions
    Spironolactone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-01
    Completion
    2022-04-29
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis
    InterventionSpironolactone; Placebo
    PhasePhase 4
    Registry statusCompleted